

FACSIMILE

STATE PHARMACEUTICALS CORPORATION

16th Floor, "Mehewara Piyasa" 41, Kirula Road, Colombo 05,Sri Lanka.

Telephone: (00) 94-11-2582509 Fax: (00) 94-11-2582496 E-Mail: pharma.manager@spc.lk

FAX TO : M/s.

DATE :

FAX NO

NO. OF PAGES	
TRANSMITTED : IF ALL PAGES NOT RECEIVED PLEASE TELEPHONE:	

BIDDING DOCUMENT FOR INVITATION OF RESTRICTED BIDS (DPC) FOR THE SUPPLY OF DRUGS FOR EMERGENCY PURCHES FROM INDIA WITH FACILITY OF INDIAN CREDIT LINE

BID NO. : DHS/ICL/X/002/2022

CLOSING AT 9.00 A.M. SRI LANKA TIME ON: 31.03.2022

State Pharmaceuticals Corporation hereby invite your lowest prices for the supply of the item/s listed in the Annex 1, which is for use in Government Medical Institutions.

Yours faithfully

STATE PHARMACEUTICALS CORPORATION OF SRI LANKA

PROCUREMENT OFFICER DHS - [PHARMACEUTICALS]



STATE PHARMACEUTICALS CORPORATION OF SRI LANKA

(ESTABLISHED UNDER THE STATE INDUSTRIAL CORPORATIONS ACT, NO. 49 OF 1957) 16th Floor, "Mehewara Piyasa" 41, Kirula Road, Colombo 05 Sri Lanka

Telephone: (00) 94-11-2582509 Fax: (00) 94-11-2582496 E-Mail: <u>pharma.manager@spc.lk</u>

Dear Sirs,

BIDDING DOCUMENT FOR INVITATION OF RESTRICTED BIDS (DPC) FOR THE SUPPLY OF DRUGS FOR EMERGENCY PROCUREMENT FROM INDIA WITH FACILITY OF INDIAN CREDIT LINE

BID NO. /BID REFERENCE : DHS/ICL/X/002/2022 CLOSING AT 9.00 am SRI LANKA TIME ON: 31.03.2022

State Pharmaceuticals Corporation hereby invite your C&F prices in USD for the supply of the item/s listed in the Annex I, which is for use in Government Medical Institutions.

TERMS AND CONDITIONS OF BID/INSTRUCTIONS TO BIDDERS

1. **SUBMISSION OF BID.**

1.1 Bid shall be submitted in one Original and One Duplicate sealed separately and marked as "Original" and "Duplicate" respectively. Both envelopes shall together be enclosed in one envelope sealed and addressed to 'Chairman/ Departmental Procurement Committee, State Pharmaceuticals Corporation of Sri Lanka, 16th Floor, "Mehewara Piyasa" 41, Kirula Road, Colombo 05 Sri Lanka.

Individual/separate bids to be submitted for each item

1.2 Bids, if sent through the Post, should be sent under registered cover. A Bidder may also personally deposit sealed Bids in the Tender Box provided for this purpose at Administration Department of the State Pharmaceuticals Corporation of Sri Lanka, 16th Floor, "Mehewara Piyasa" 41, Kirula Road, Colombo 05 Sri Lanka.

The left-hand top-corner of the envelopes should indicate the Bid Reference, SR number of relevant item and the closing date of Bid. Bids should be received on or before the closing date and time of Bid. Late Bids will not be entertained under any circumstances. The Corporation shall not accept responsibility for the Bid misplacement or premature opening of Bids if the envelopes have not been marked as given above.

2. FORMAT OF BID/BID SUBMISSION FORM & PRICE SCHEDULE

- 02.1 Bids should be submitted according to the format given in **Annex IIA & IIB**.
- Dids which are not in the prescribed format or are not in strict conformity with the terms, conditions and specifications laid-down in this Bid shall be rejected.
- 02.3 The Bid shall contain no interlineations, or even writing except as necessary to correct errors made by the Bidder in which case such corrections shall be initialled by the person or persons signing the bid.
- O2.4 All Bids, literature etc., should be in the English Language.
- O2.5 The bid submitted should be duly signed and endorsed by the Bidder himself (the name and designation of the signatory, should be indicated)

VALIDITY OF OFFER

Bidders should keep their offers valid for acceptance for a period of at least 180 days from the date of closing of tender. No increase in price will be permitted after tender award.

3. ELIGIBLE GOODS AND REGISTRATION

- 4.1 WITH THE NATIONAL MEDICINES REGULATORY AUTHORITY (NMRA)
 - (a) All Pharmaceutical Products imported to Sri Lanka should be registered with the National Medicines Regulatory Authority of Sri Lanka.
 - (b) A Certified copy of the NMRA registration Certificate certified by Attorney-at-Law, Commissioner of Oaths or Justice of Peace should be submitted along with the
 - (c) All items shall be of Indian Origin

5. FRESH STOCKS AND SHELF LIFE

- 5.1 Supplies should be conformed to the stipulated specifications and shelf life as stated in Annex 1. Residual shelf life should be at least 75% at the time of receipt of goods at MSD.
- 5.2 Corporation reserves the right to call for free replacement of goods supplied with inadequate residual shelf life, reimbursement the cost of goods or reject such deliveries.

6. COUNTRY OF ORIGIN AND NAME OF MANUFACTURER

The Country of Origin should be India and Name of Manufacturer should be indicated in the Bid Form at Annex II B.

7. BID OPENING

- 7.1 Bids will be opened immediately after closing, at the Head Office of the State Pharmaceuticals Corporation at 16th Floor, "Mehewara Piyasa" 41, Kirula Road, Colombo 05 Sri Lanka at the date and time specified in **Annex 1**.
- 7.2 The bidder or their authorized representatives will be permitted to be present at the opening of Bids.
 - 7.3 Only the copy of the bid marked 'Original' will be opened at the time of opening of Bids.
 - 7.4 The Bid Opening Committee who opens the bids will read out (or cause to be read out) to those present, the name of each Bidder as well as the amount quoted together with discounts, if any.

7.5 Any other detail which the Bid Opening Committee determines as necessary will be read out.

8. REIMBURSEMENT

- 8.1 Corporation reserves the right to call for reimbursement in the event of short packing, loss/damage or deterioration of goods supplied within the shelf-life, also for packs which cannot be identified due to labels falling off or items with incorrect labelling.
- 8.2. All quality problems/complaints should be confirmed by the National Medicines Regulatory Authority (NMRA)/ Technical Advisory Committee (TAC) of Sri Lanka/ SPC Quality Assurance Laboratory or any other Authority as decided by the Ministry of Health of Sri Lanka.
 - a) In the event of receipt of a complaint samples will be tested by NMQAL, and follow the recall procedure approved by the Ministry of Health and will be destroyed according to section 72 of Drug regulations.
 - b) In case of withdrawals due to quality failure Suppliers should ensure that the value of entire quantity of either the withdrawn batches or products would be totally reimbursed with an additional 25% of the total value concerned as an Administrative Cost.

9. PERFORMANCE BOND

- 9.1 The successful Bidder shall within 07 days from the notification of award should submit an unconditional Performance Bond up to 25% of the total value of award and should be valid 3months beyond the last delivery date
 - Failure to comply with this request shall constitute sufficient grounds for the Corporation to cancel such award .
- 9.2 However, the **Departmental Procurement Committee** reserves the Right to increase/decrease the required Performance Bond at their discretion.
- 9.3 The Performance Bond shall be as per specimen **Annexure IV -** and shall be issued by one of the institution given at para 5.2.
- 9.4 Claims on the Performance Bond will be made by the Corporation on the very first instance the supplier fails to comply with the terms and conditions of Bid or Purchase Order.

10. CONTRACT AND ARBITRATION

(A) CONTRACT

The successful supplier should agree to enter into a Contract/Agreement with the State Pharmaceuticals Corporation.

(B) ARBITRATION

If during the continuance of this Contract or at any time after the termination thereof, any difference or disputes which may arise between the parties hereto in regard to this interpretation of any of the provisions herein, contained or any other matter or thing relating to this contract (other than any difference or dispute in respect of which a decision of the Chairman of the State Pharmaceuticals Corporation of Sri Lanka, is declared to be final and

binding on the parties hereto) such difference or dispute shall be forthwith referred to an Arbitral Tribunal in Sri Lanka. Composition of the Arbitral Tribunal, Jurisdiction of the Arbitral Tribunal, Conduct of Arbitration Proceedings, awards and any other matters relating to the Arbitration shall abide by Arbitration Act No. 11 of 1995 of the Democratic Socialist Republic of Sri Lanka. The place of Arbitration shall be in Sri Lanka.

11. PACKING AND STORAGE CONDITIONS

- i. Pack Size offered should conform to requirements. Bids for alternate pack sizes may be rejected. Export-worthy packing which will prevent damage in transit should be used. Details of nature of packing should be given.
- ii. Packing of all items should be suitable for storage and use under tropical conditions. Final packing should indicate the required storage temperature for goods which require Refrigeration/ Cool Room/ Freezer Storage enabling the cargo handling staff to arrange proper storage for such goods immediately on receipt.
- iii. Containers and closures used should be of such quality so as not to react with the contents while in storage under tropical conditions.
- iv. Large tablets (over 250mg in weight) in bulk packs (over 500 tablets per pack) should not be packed in glass bottles as glass bottles are likely to be damaged in transit. Such items should be packed in sealed polyethylene film bags inserted in to strong airtight metal or plastic containers.
- v. Sri Lankan ambient storage conditions are in the ranges of 30°C +/- 2°C temperature and 75% +/-5% relative humidity.
- vii. The items which have to be stored between 2° C 8° C should be delivered with cold chain monitors.
- viii. The Recommended storage mentioned on the Product label should be maintained at all levels including in transit and storage condition should be clearly shown on Invoice. All outer carton and inner box should contain the following information.
 - (a) Description of the Item
 - (b) Date of Manufacturer
 - (c) Date of Expiry
 - (d) Batch No.
 - (e) Name and Address of manufacturer

12. LABELLING

- All labels should be printed in English Language and the labeling requirements should be according to the specifications required for registration at **NMRA** as follows.
 - (a) The approved name found in official pharmacopoeias or formularies. (The source should be stated in abbreviations: e.g. BP, USP,...etc.)
 - (b) The Brand Name
 - (c) List of the active ingredients showing:
 - i. Amount of each presenting each dosage unit
 - ii. A Statements of the nett contents (e.g. number of dosage units, weight or volume)
 - (d) Any special storage conditions that may be necessary
 - (e) Warnings and precautions that may be necessary
 - (f) The Date of Manufacture

- (g) The Date of expiry
- (h) The batch or lot number assigned by the manufacturer and
- (i) The name and Address of the manufacturer.

12.2 Anaesthetic Products

- (1) Generic Name of drug should be printed large and clear.
- (2) All ampoules should be effectively pre-cut.
- (3) Labels should be effectively pasted to avoid loosening when in contact with water. STICKER LABELS to be provided for Operating Theatre use.
- (4) Colour coding of sticker labels should be in accordance with the "Standard Specification for User Applied Drug Labels in **Anaesthesis**" set out by the American Society for Testing and Materials. ASTM D4774-88.

e.g. Relaxants Red Vasopressors Violet

Opiates Blue Local Anaesthetics Gray

Lignocaine with adrenaline and adrenaline ampoules should have a distinct red band and red lettering.

Sticker labels for syringes should be provided for the following drugs:-

Thiopentone Pancuronium
Diazepam Atracurium
Midazolam Vacuronium
Ketamine Neostigmine
Suxamethonium Atropine

Tubarine

13. PAYMENT

Will be arrange as per the terms and condition of Indian credit Line facility agreement with Government of Sri Lanka. Payment will be made in Indian Rupee equivalent to offer price in USD.

14. TENDER AWARD

Awards are made to suppliers taking into consideration among other factors, prices quoted, past performance, quality of samples, delivery offered, product registration etc. And the decision of the Procurement Committee is final.

The Procurement Committee reserves to itself the right without question to:-

- (a) Accept any bid, or portion of a bid,
- (b) Accept portions of more than one bid
- (c) Reject all or any bids
- (d) Direct that fresh bids be called for
- (e) Cancel the bid

The relevant **Procurement Committee** reserves the right, at time of award to decrease/increase the quantity required, by 25% without any change in price or other terms and conditions.

In case lowest evaluated responsive supplier is Bidding for a product which has not been supplied before, the relevant **Procurement Committee** reserves the right to purchase only

part quantity from such supplier and to get a feedback from the end users to decide on the balance quantity.

However, in such cases the price offered for the total amount should be maintained for the smaller quantity.

15. <u>DELIVERY</u>

Reference **Annex I** - Successful bidders should conform strictly to delivery dates. Failure to do so will result in forfeiture of the Performance Bond and/or cancellation of the award.

If awarded supplier is unable to adhere to the delivery schedule due to no fault of the SPC would result in the supplier being surcharged as per the condition mentioned under "condition of supply" in Annex I.

16.. TESTING OF BATCH SAMPLES

In the case of distribution to Hospitals/ State Institutions random batch samples and random post-marketing samples of all goods supplied will be tested at the NMQAL/ Quality Assurance & Research Laboratory of the State Pharmaceuticals Corporation and reports on its suitability issued. The findings of the reports will be final and binding. Goods reported as unsuitable and not conforming to the laid down specifications will be rejected and subsequently destroyed. The suppliers should agree to refund its landed cost plus an additional 25% as an Administrative cost within 30 days from the date of intimation.

17. QUALITY CERTIFICATE

- (a) Corporation reserves the right to nominate Independent Competent Authorities for the issue of pre-shipment Certification (Certificate of Quality, Quantity and Loading). In such an event, the cost of **such certification** must be borne by the supplier and should be included in the Bid (**Annex 11B**).
- (b) The Secretary, Ministry of Health, Sri Lanka reserves the right to nominate suitable persons to inspect the production and quality control facilities of bidders and manufacturers and their records. Bidders, who refuse permission to our nominees to carry out such an audit will be automatically disqualified.
- (c) The expenses involved. In the inspections should be borne by the manufacturer/ supplier.

18. WHO CERTIFICATION SCHEME FOR QUALITY OF PHARMACEUTICAL PRODUCTS MOVING IN INTERNATIONAL COMMERCE

- (a) A certificate of Pharmaceutical Product (CPP) issued by the Competent Authority in the manufacturer's country confirming that the item bided has been authorized to be placed in the market for sale and use in the country of manufacture, should be submitted along with the Bid.
- (a) The certificate of Pharmaceutical Product should also certify that the Manufacturing Plant in which the product is produced is subject to inspection at suitable intervals, and that the manufacturer conforms to the requirement for Good Practices in manufacture and quality control as recommended by the World Health Organization in respect of products to be sold or distributed within the country of origin or to be exported.
- (b) All batches offered should conform to the requirements of the Competent Authority for sale or distribution within the country of manufacture or where appropriate to published specifications, e.g.: BP/USP/IP or to established specifications provided by the manufacturer. These certificates should indicate the name and dosage form of the product, the batch number,

the date of manufacture, date of expiry, storage conditions, date of packaging, labeling, nature of the container, results of analysis and other data (BATCH CERTIFICATES).

19. PRODUCT LIABILITY

In the event of an order being placed, the supplier should indemnify the State Pharmaceuticals Corporation of Sri Lanka against all product liability claims arising out of the items supplied on his bid. E.g. due to incorrect labelling, deviation from agreed specifications etc.

1. PATENT RIGHTS (AND OTHER THIRD PARTY RIGHTS) AND ROYALTIES

The suppliers shall at all times indemnify and keep this Corporation indemnified against any and all claims arising at any time on Account of Patent rights or other rights, whether from manufacturers or others, from the use of the supplied goods in Sri Lanka.

21. BIDS FROM THOSE OTHER THAN MANUFACTURERS

Bids for supply of goods which are not manufactured by the bidder should be supported by a Certificate of Authority issued by the Manufacturer at the time of submitting bidding documents indicating that the bidder has been duly authorized to supply the goods bided for. Failure to comply will result in the offer being rejected.

22. TERMS & CONDITIONS AND CLARIFICATION

Prospective Bidders should acquaint themselves, fully with these terms and conditions and if any further clarification is required please contact the undersigned, No plea of lack of information or insufficient information will be entertained at any stage.

23. EXAMINATION, EVALUATION AND COMPARISON OF OFFERS

23.1 The purpose of bid evaluation is to determine the lowest evaluated bid from the substantially responsive bids received.

i) **Preliminary examination**

The Bid received will be examined by the Technical Evaluation Committee appointed for each bid to determine whether they are complete, whether they are from eligible bidders, whether the document has been properly signed, whether any computational errors and whether the samples are provided if required and whether the specimen Bid form at **Annex 11 (A)** has been followed and the price schedule as per **Annex 11 (B)** has been followed.

ii) Prior to detailed evaluation

The TEC will determine the substantial responsiveness of each offer to the bidding documents as pursuant to clause 26.1.(i). A substantially responsive bid is one, which conform to all the conditions described in clause 26.1 (i) without any deviation. A bid determined as not substantially responsive will be rejected and may not subsequently be made responsive by the bidder by correction of the non-conformity.

The offers, which are previously determined to be substantially responsive to clauses.

23.2 (i), (ii) will be further evaluated.

- iii) The TEC and the Corporation will also examine the Bids in order to ensure the correctness of the Bids. Arithmetical errors, if any, will be corrected on the following basis;
 - a) If Discrepancy is between Unit Price and Total Price, then the Unit Price shall prevail and the Total Price will be corrected.

- b) If Discrepancy is between words and figures, the amount in words will prevail.
- c) If a Discrepancy appears between the original bid and the duplicate, the original will prevail.
- iv) All the items offered in Annex 11B should conform strictly to the technical specifications set out in the Annex 1 of this document and will be taken in to account at the time of evaluation.
- Unless specifically stated in this document any other relevant Terms & Conditions of Bid/Instructions to Bidders any annexures mentioned in 'Global Bid Document Pharmaceutical DPC' available for perusal at web site of SPC, Home page, main menu under the Tab 'Tenders' in www.spc.lk and Guide Lines for Procurement of Pharmaceuticals issued by the Government with its subsequent amendments/revisions will be applicable.
- In the event of conflict between Global Bid Document Pharmaceutical DPC, Procurement Guide Line for Procurement of Pharmaceuticals and Medical Devices Procurement Guide Lines issued by the Government 2006, and subsequent Amendments/Supplements this 'Bidding Document for Invitation of Restricted Bids' shall prevail.

Abbreviations: SPC; State Pharmaceuticals Corporation, MSD; Medical Supplies Division.

Yours faithfully

STATE PHARMACEUTICALS CORPORATION OF SRI LANKA

PROCUREMENT OFFICER DHS - [PHARMACEUTICALS]

Telephone: (00) 94-11-2582509 Fax: (00) 94-11-2582496

E-MAIL address: dgmpharma@spc.lk and pharma.manager@spc.lk

CC :

ANNEX I

BID NO./BID REFERENCE DHS/ICL/X/002/2022

Closing on: 31.03.2022 at 09.00 am

MSD ORDER LIST NO. - 2022/SPC/X/R/P/

SR No.	Item Description/Specifications	Quantity	Delivery Schedule

As listed below	

Sufficient quantity of Representative samples for the item to be submitted for the evaluation as tender samples.

Bid validity period: Bid should be valid till 27.09.2022 [180 days of tender closing]

Bid Evaluation Summary sheet should be submitted with the Bid (Please refer SPC website for more details)

MSD CONDITIONS OF SUPPLY

- 1. The consignments supplied in respect of an order concerned, shall exactly match with the reference sample submitted and the product information (item descriptions, shelf life/warranty where applicable, manufacturer's name, country of manufacture, country of origin, etc.) provided in the bid document by the supplier, which has been accepted by the procurement committee, and included in the Indent / Purchase Order (PO), issued by SPC.
- 2. All items shall be supplied, sourcing from the manufacturer and country of manufacturer, stated in the Purchase Order (PO)/Indent of SPC and wherever applicable shall have a valid product registration or waiver of registration from NMRA.
- 3. Maintaining the validity of the product registration during the period of supply(delivery schedule), obtaining waiver of registration &/ import license / manufacture licensing at NMRA, is a prerequisite for the supply of surgical, pharmaceutical and relevant laboratory items. Hence all suppliers shall produce relevant valid registration certificates/licenses, when requested by MSD/SPC.
 - When the validity of the product/manufacturing licenses and registrations of NMRA (eg; manufacturing license, product registration and GMP certificates), of local manufacturers / local suppliers, lapses during the year or during the period of supply (delivery schedule), it shall be extended / renewed by the supplier. A certified copies of afore mentioned valid certificates shall be submitted to MSD by the supplier when deliveries are made.
- 4. If MSD decides to accept a part or full consignment, with deviations from certain tender conditions (eg: with regard to labeling/packaging etc.) due to an urgency, that shall be done subject to, either rectifying the defect within 05 working days by the supplier, or recovering the total cost [a] of rectifying the defect by MSD (via a duly contracted third party providing such services), from the supplier with a 25% surcharge on the labeling cost. (total charge = [a]+[a]x0.25) or 2% of the invoiced value, whichever is the highest.
- 5. The specifications of the product offered in the bid, by the supplier shall match with the tender specifications for the item and any form of alternate offers will not be entertained.

Shelf life & Warrantees

6.Freshly manufactured stocks of the product shall be supplied; thereby the residual Shelf Life (shelf life remaining at the time of delivery of goods in Sri Lanka/MSD stores in case of local supplies) of the product, shall be 75% of the shelf life requested (specified in order/Indent/PO).

In respect of the items with requested shelf life equal or more than 24 months, any deficit between the residual shelf life and requested shelf, shall not be more than 04 months.

In the violation of the above tender condition, SPC/MSD reserves the right to accept a reduced quantity, that is usable (as per the consumption rate) up to three months before the expiry of same and will subject to application of a penalty (as clause No. 28).

When the shelf life is not specified in the indent/PO/item spec; the requested shelf life shall be considered as, 36 months for surgical items and 24 months for pharma. / laboratory items.

Standards & Quality

- 7. <u>Standards</u>: In addition to Pharmacopoeial Standards that are indicated in the item specifications, other Pharmacopoeial Standards that are registered at National Medicines Regulatory Authority in Sri Lanka are also acceptable when no bidders have quoted for the standard specified in the item specification.
- 8. Any product deficient of its sub components/ accessories, not at the specified quality standards or all its components not unitized appropriately in packaging (as a set), shall be rejected.
- 9. Withdrawal from use of items due to quality failure found as manufacturer's fault:
 - (a). In case of batch withdrawal, **value of entire batch quantity supplied** shall be recovered from the supplier.
 - (b). In case of product withdrawal, **value of entire product quantity** supplied shall be recovered from the supplier.
 - (c). In the event of either a) or b) above, supplier shall be surcharged the total **cost involved for MSD**, **of the quality failed supplies** with 25% administrative surcharge of the same.
 - 10. The storage conditions and the packing requirements of the product shall conform to the information given by the manufacturer and accepted by NMRA for the product registration or shall conform to the information submitted for waiver of registration granted by NMRA in exceptional circumstances. (refer clause No.17)

If the offered product, deviate from NMRA registered product features, supplier must provide with the bid, a declaration to certify the NMRA accepted product details such as; storage conditions, pack details/contents/sizes and standard batch quantity/size of the product.

- 11. Immediately after delivery at MSD, the consignments shall be subjected to testing appropriately drawn, one random batch sample (Post-delivery sample) of the consignment at a government/semi-government/accredited laboratory.(to be selectively applied for Surgical & Lab items, depending on availability of testing methodology & facilities) If the sample is found to be substandard, random batch samples will be tested from all the batches/ lots in the consignment, and entire expenses on such tests, like value of samples, transport, sampling & testing charges, etc, will be recovered from the supplier.
- 12. Consignments supplied to MSD violating the storage conditions indicated on product labels and/or product information leaflet (as accepted for product registration at NMRA), shall be considered as quality affected consignments and quality assurance of such consignments shall be carried out by post-delivery testing at government / semi government laboratory in Sri Lanka or at an accredited laboratory (foreign/local). All the expenses on such an event, including storage cost shall be borne by the supplier. If found to be quality affected the consignment will be treated as quality failed (as clause No.09).

Pack size, Labeling & Packaging

- 13. Offers for pack sizes at a lower level(smaller quantity per pack) than the pack size specified in the item description/specification and MSD order List, are also acceptable, but higher level (larger quantity per pack) pack sizes will not be entertained unless otherwise offered with the original bid and accepted by the procurement committee, with the concurrence of MSD.
- 14. Description of the Item, Date of Manufacture, Date of Expiry, Batch No, Name and address of manufacturer shall be clearly marked on the outer covering of the individual/innermost pack containing the minimum unit of measure, including blister & strip cards and on the outer cover of the carton/box. Any deviations of the Date of Manufacture (DOM)/ Date of Expiry(DOE)declared in the offer shall be approved by MSD and DOM & DOE shall consist of at least the year & month.
- 15. All outer most cartons (shipping packages) shall bear the Batch No, and Date of Expiry in size 1.5cm letters / figures in prominently visible manner. This may be printed, stenciled or label properly affixed.
- 16. In case of receiving goods under inappropriate packaging conditions(not in good order), was to be sorted out by MSD to select the items in good order by 100% checking/handling of the consignment, all expenses incurred to MSD in such an event (including demurrage charges, cold stores charges, labor charges etc. or any other charges incurred until goods are ready for acceptance), have to be paid to MSD by the local supplier, before attending to checking the consignment 100%, by MSD.

In respect of SPC imported supplies, if the local agent does not follow suit as above, such extra expenses incurred to MSD shall be recovered from the supplier by SPC and refund to MSD.

Storage Conditions & Temperature

17. If the storage temperature & conditions are not specified in the item specification, NMRA accepted product storage conditions, shall conform to Sri Lankan ambient storage conditions in the ranges of 30° c +/- 2° c temperature and 75% +/-5% relative humidity. The product storage conditions shall be clearly indicated at all levels of labels/packages/boxes.

Maintenance of Cold Chain;

- a.In case of cold storage items, cold chain monitors (temperature recording devices) shall be included for each carton and the cold chain shall be maintained according to the manufacturer's instructions during storage, transport and delivery.
- b.Supplier shall use suitable prominently visible identification marks of international standard, with appropriate colours and sizes for easy identification of cold cargo. Supplier shall use standardized **USB Devices** for temperature data logging inside the packages and shall provide free of charge, data logger readers **&/ software (reading apps compatible with Windows-07/latest)** to wharf department of SPC in advance, to enable examining the maintenance of cold chain in transit, and before taking over the consignment by MSD.
- c.If the cold chain break is observed at the time of taking over the consignments by MSD, such consignments shall be rejected, indicating the reason on the relevant **WDN or copy of the delivery documents.** In such an event, the SPC shall arrange necessary cold storage for the consignment until 'observed cold chain break' is investigated leading to acceptance / total rejection of consignment and the expenses born by MSD / SPC in arranging the cold storage shall be recovered from the supplier.
 - d.The vehicles transporting cold cargo to MSD shall be equipped with temperature monitoring devices and the vehicle shall have NMRA approval for transport of pharmaceuticals.

- e.The suppliers shall dispatch consignments of the items, which require cold chain maintenance, to arrive in Sri Lanka during Monday to Thursday to avoid additional demurrage & storage charges during weekends, during which MSD stores is closed. In case of non-compliance of this condition, any additional expenses incurred to MSD and SPC, to Custom clear/store/receive such consignments shall be recovered from the supplier.
- 18. In respect of the products requiring controlled temperature storage (Eg. < 25° c, $2-25^{\circ}$ c, $15-20^{\circ}$ c/ 30° c, $2-8^{\circ}$ c etc.), supplier shall provide MSD with latest product stability study reports with the invoice of the consignment.(report shall include studies; at 30° c +/- 2° c & 75% +/- 5% RH for **AC stored** items and at 25° c +/- 2° c & 60% +/- 5% RH for **Cold stored** items. It shall be a true copy of the latest report submitted to NMRA or a report issued within last 05 years).

Delivery Requirements

19. All items shall be supplied as per the latest/final delivery schedule, communicated to the supplier, as an amended Indent/PO delivery schedule (if not amended, original schedule in the Indent/PO will apply) mutually agreed between MSD& SPC, at the time of establishing the payment terms (L/C, DP, TT, etc). Any deviation from this agreed delivery schedule shall be treated as a defaulted delivery.

Contravening the above directions, if the delivery schedule is violated by the supplier for no fault of MSD/SPC/MOH and in the event MSD decides to accept any such consignment in full or part thereof, that is delivered after the due delivery date, Condition No. 21 on delayed deliveries, shall be applied.

- 20. All consignments shall be delivered at Medical Supplies Division or an alternate receiving point as directed.
- 21. Defaulted consignments with respect to delivery schedule shall only be considered for acceptance, subject to a penalty imposed for the delay due to suppliers fault, allowing a grace period up to two weeks. Consignments delivered after that grace period shall be considered for acceptance subject to a penalty 8 to the supplier as described below;
- (a). A penalty of 0.5% per day of the consignment value, calculated commencing from the 15th day up to 60th day delay from the due delivery date, as per the indent/PO or its' latest amended delivery schedules.
- (b). When the delay exceeds 60 days purchase order will be considered as automatically cancelled, on defaulted performance. In such a situation, MSD reserve the right to recover liquidated damages or to revoke the cancellation (eg. if payments have been released prior to such a cancellation), and accept the consignment subject to a 25% admin surcharge.
- 22. The extension of L/C's overstepping delivery schedules in the Indent/PO/its' amendments, shall not in any way affect the recovery of late delivery charges, as per Condition No. 21 (regarding defaulted consignments) and any other direct or indirect additional costs/liquidated damages, relating/consequent to extension of L/C
- 23. When adequate storage space is not available at MSD, to accept a delivery defaulted consignment (deviating from the delivery schedule in the Indent/PO/its' amendments) under the condition No. 21, any additional expenses caused to MSD or SPC in arranging temporary external storage and other expenses (eg. demurrage, detention, container storage, re-handling cum transport, etc.) shall be borne by the supplier.

Documents & Information

- 24. MSD Order No, Item Description, SR No, Batch No., Date of Manufacture, Date of Expiry and product Storage Condition, shall be indicated in all Supply Invoices and detailed Packing Lists.
- 25. The supplier shall submit all shipping documents to (Including Bills of Lading / Draft Air Way Bills etc.) SPC Imports department and MSD by e-mail (follow instructions in website www.msd.gov.lk), at least 03 days before the Expected Time of Arrival (ETA) of sea freighted consignments & 02 days before the ETA of Air freighted consignments.
- 26. If it is not complied or the information so provided are found to be incomplete/false, the grace period (for supply delays) mentioned in the clause 21 will not be applicable.

All the documents listed as a requirement or Indian Credit Line facility should be provided soon after intimation of the order. Documents required is listed and annex as annexures and Form A,B,C,D,E and Excel sheet.

Common conditions

- 27. In addition to the general conditions of supply given herein, item/order-list specific amendments, exclusions or additions to the same, stated in the covering letter of the order list and any other relevant conditions as per the tender document issued by SPC, are also applicable. The order/item specific; new conditions or amendments to General Order Conditions, will be included in the order list itself and as a remark entry in the MSMIS order records.
- 28. Administrative surcharge of 25%(on the value of goods), will be applied for tender condition violations that cause deficiencies in supply with respect to; quality, standards & specifications, short packing & short supply or delayed delivery as per the cabinet decision.

Abbreviations: NMRA; National Medicines Regulatory Authority/Sri Lanka, SPC; State Pharmaceuticals Corporation, MSD; Medical Supplies Division/Ministry of Health-Sri Lanka.

Annex II A

SPECIMEN FORM OF BID (SUPPLIES)

Chairman,	
Departmental Procui	rement Committee
'	
	BID FOR THE SUPPLY OF
	BID NO./BID REFERENCE
	DID NO./DID NEI ENENOE

1.I/ We, the undersigned, having read and fully acquainted myself/ourselves with the contents of the

Terms and Conditions of Bid/Instructions to Bidders and Contract and Annex I where specifications and delivery of items required pertaining to the above Bid, hereby undertake to supply the goods referred to therein, in accordance with the aforesaid Instructions, Terms and Conditions as per price quoted in the attached Annex II B.

	-	
		nfirm that this offer shall be open for acceptance until
3. I	/We atta	ch hereto the following documents as part of my/our Bid:
	(1)	Price schedules (as per Annex II B – Bid Form
	(11)	Documentary evidence to establish Registration of product with the National Medicines Regulatory Authority Certificate No
- 41 - 1 -	(III)	Documentary evidence to establish that goods offered are from an eligible source and
origin.		(Document as required in Para. 4 of the Terms & conditions of the Bid).
	(IV)	Any other documents (give details).
		erstand that you are not bound to accept the lowest bid and that you reserve the right to reject Bids or to accept any part of a Bid without assigning any reasons thereof.
5. V	Ve under	rtake to adhere to the Delivery Schedule indicated.
6. N	-	ank Reference is as follows:
5	ignature	
	of Bidder	
Addres	SS:	

STATE PHARMACEUTICALS CORPORATION - BID FORM

ANNEX 11 (B)

BID NO./BI	D REFERENCE		CL	OSING ON:	•	be submitted in	duplicate)		
NAME & AI	ODRESS OF MANUFACTURER ODRESS OF BIDDER :		Q2			(Bidders shoul Offers which ar			-
SR NO./ITEM NO.	FULL DESCRIPTION OF ITEM OFFERED, THE STANDARD AND THE STORAGE TEMPERATURE	3 PACK SIZE OFFERED	4 QTY OFFERED	5 PROBABLE SHIPMENT/D ELIVERY DATE	6 ZUNIT PRICE & CURRENCY (DELIVERY PRICE TO MSD STORES)	TOTAL DELIVERY PRICE TO MSD STORES	8 NMRA REGISTR ATION CERTIFIC ATE NO. & DATE OF EXPIRY	9 SHELF LIFE	10 COUNTRY OF ORIGIN
Indicate 2. Indicate 3. Quotation	nspection Certificate (If not inclu from whom independent Pre-sh date when samples were submit on Valid upto :	ted:	cate of Quality, Quantit	y and Loading w	ill be submitted				

We confirm that we have read and understood the terms, conditions and specifications covering this tender and submitted our offer accordingly. We are not listed as defaulted/ black-listed Bidder in any Government Institution in Sri Lanka. "In the event of goods being rejected due to un-acceptable quality, reimbursement of its value and an additional 25% of the total value at landed cost as an administrative charge will be made".

Name of Bidder	:
Signature of Bidder (With Name and Designation	: of Signatory)
Official Stamp of Bidder	:
Postal Address of Bidder	:
Telephone No.	:
E-mail	:
Fax No.	:

(Inform your terms and conditions and special instructions for opening Letters of Credit in the event of an award in your favour)

NOTE

Name of Bankers with Account No.

Beneficiary

1. Storage temperature of the offered items should be prominently indicated in the column No. 2.

SPECIMEN FORM OF PERFORMANCE BANK GUARANTEE

(UNCONDITIONAL)

BOND NUMBER: DATE:	
SUM GUARANTEED:	
To:(Nan	ne of employer)
(Address of	of employer)
Whereasname and addre (hereinafter called "the contractor") has undertaken, in persuance to execute(name of contract) (hereinafter calle	of contract No dated
And whereas it has been stipulated by you in the said Contract the Bank Guarantee by a recognised Bank for the sum specified the obligations in accordance with the Contract;	_
And whereas we have agreed to give the Contractor such a Bank G	uarantee;
Now therefore we hereby affirm that we are the Guarantor at Contractor, up to a total of	(amount of Guarantee) such sum being payable in the type and and we undertake to pay you, upon your sum or sums within the limits of tout your needing to prove or to show
We hereby waive the necessity of your demanding the said debt with the demand.	from the contractor before presenting us
We further agree that no change or addition to or other modificat Works to be performed thereunder or of any of the Contract doc and the Contractor shall in any way release us from any liability waive notice or any such change, addition or modification.	ument which may be made between you
This guarantee shall be valid until a date 28 days from the date of	issue of the taking over Certificate.
Signature and the Seal of the Guarantor:	
Name of the Bank:	
Address	
Date:	
Witness:	

C	/ A	٠.
\Pa	/ A1	ır
Jua	/ A A.	ш

DEMOCRATIC SOCIALIST REPUBLIC OF SRI LANKA

Our Ref No.	:	Date:
Tender No	:	

This AGREEMENT made and entered into between the State Pharmaceuticals Corporation having the Registered office at 16th Floor, "Mehewara Piyasa", 41, Kiur;a Road, Colombo 05, Sri Lanka (hereinafter called the "SPC" which term or expression shall mean and include the said State Pharmaceuticals Corporation and its successors and permitted assigns) of the One Part and M/s. business under the time, style and firm of a company duly registered and carrying business (hereinafter called "the supplier" and which term or expression shall mean and include the said and its/their/its heirs executors administrator and permitted assign/successors in business or permitted assigns) of the Other – Part.

Whereas the State Pharmaceuticals Corporation has accepted the tender of M/s. for the supply and delivery of in the manner and quantities as per the attached Indent for USD marked hereof.

NOW IT IS HEREBY AGREED AS FOLLOWS:

- 1. The following documents: -
 - (a) Conditions of contract marked 1
 - (b) Bid documents marked 2
 - (c) Copy of Indent marked 3

(hereinafter called "the Contract Documents") showing and describing the nature and scope of the Agreement duly signed by both parties shall be deemed to form and be read and construed as part and parcel of this Agreement.

2. In consideration of the payment to be made by SPC to the supplier the contract sum hereinafter mentioned the supplier hereby covenants with SPC to supply and deliver the goods in conformity in all respects with the provisions of this contract.

	uch supply and delivery of the goods according to the and in the manner and at the times hereinafter		
and the supplier and may only b	lefined constitutes the entire agreement between SPC be modified or repealed by formal agreement in rties or their authorized representatives.		
In witness whereof the official Seal to be affixed and the signature of the Authorized officers of the State Pharmaceuticals Corporation of Sri Lanka have set their hands and Suppliers has placed its hand/caused its Common Seal to be affixed hereunto and to two other of the same tenor on this			
The Common Seal of M/s	herein.		
1President/Managing Direc	etor/C.E.O.		
2 Director	•••••		
Witnesses			
<u>Signature</u>	Name, Address and ID No.		
1	•••••••		
2			

Contd...3/-

- 3 -

Annexure 1

CONDITIONS OF CONTRACT

- 1. SCOPE OF CONTRACT
 - Provide Pharmaceuticals for the Department of Health Services as per The Tender No. -----closed on hereof.
- 2. GOODS
- 2.1 Supply should be from fresh stocks of recent manufacture conforming to the stipulations in the schedule marked 3 and the samples submitted.
- 2.2 The goods supplied should have at least ... month's residual shelf life at the time of receipt in Sri Lanka
- 2.3 Goods supplied should meet the Dissolution Bio equivalence test requirements where applicable.
- 2.4 SPC reserves the right to: -
 - (a) Reject goods supplied with an inadequate shelf life and refrain from clearance from port or,
 - (b) Call for free replacement of goods or reimbursement of cost so supplied, which do not conform to required standards.
- 3 FREE REPLACEMENT AND /OR REIMBURSEMENT DUE TO QUALITY ISSUE
- 3.1 SPC reserves the right to call for the replacement or reimbursement in the event of
 - 3.1.1 Short packing
 - 3.1.2. Loss damage or deterioration of goods supplied (within Shelf Life)
 - 3.1.3. Packs which cannot be identified due to labels falling off.
 - 3.1.4. Goods supplied fails to perform or meet requirements of the specification to the satisfaction of SPC. (Quality/Standard)
- 3.2 In the event of quality problem, Batch samples would be tested by SPC/its authorized personnel at the NMQAL or its fitness for use will be determined by an expert committee appointed by the relevant Authority.

Samples from the available batches will be retained by SPC and the balance will be destroyed by authorized officers in the presence of Local Agent and a certificate of destruction issued by SPC following destruction.

In case of Batch/Product withdrawals due to quality failure the supplier should reimburse SPC the total value of the entire quantity of either withdrawn batches of withdrawn product with an additional 25% of the total value concerned as an Administrative Cost.

3.2 Withdrawal form use of items due to quality failure found as manufacturer's fault.

- (a) In case of batch withdrawal, value of entire batch quantity supplied shall be recovered from the supplier.
- (b) In case of product withdrawal, value of entire product quantity supplied shall be recovered⁸ from the supplier.
- (c) In the event of either a) or b) above supplier shall be surcharged⁸ the total **cost involved** for MSD, of the quality failed supplier with 25% administrative surcharge of the same.

4 VARIATION

The SPC may at the time of Award increase or decrease the order by up to 25% without being subject to any change in price or terms and conditions hereof.

5 PACKING AND STORAGE

- 5.1 Packing of all items should be suitable for storage and use under tropical conditions and sufficient marking should be made on the cases or containers in order to prevent possible mistakes regarding proper storage during transit, particularly for items requiring refrigeration or cool storage.
- 5.2 Containers and closures used should be of such quality so as not to react with the contents while in storage under tropical conditions.
- 5.3 Deleted.
- 5.4 Export packing should be in seaworthy strong cases or cartons to prevent damage in transit and should:-
 - 5.4.1 Indicate recommended storage temperature for goods which require cool/cold or freezer storage.
 - 5.4.2 Stenciled with red bands in the form of a cross on each face.
 - 5.4.3 Carry shipping marks details provided by SPC with order.
 - 5.4.4 Be palletized and shrink wrapped if it is Bag Cargo.
 - 5.4.5 Should carry Batch No./Exp. Date.
- 5.5 Approved packing material as per bid document should be used. Use of Rice Straw or other vegetable matter as packing is strictly prohibited (as per regulations passed under the Plant Protection Ordinance Chapter 447). In the event of such material being used extra costs incurred by SPC by way of fumigation charges, penalty rates, demurrage etc., in clearing such consignment from the port would be debited and payable as extra costs by the supplier.

6. LABELLING

- 6.1 All labels should be printed in English Language and the labeling requirements should be according to the specifications required for registration at NMRA as follows.
 - a) The approved name found in official pharmacopoeias or formularies. (The source

should be stated in abbreviations; e.g. BP or USP etc...)

- b) The brand name
- c) List of the active ingredients showing;
 - a) The amount of each present in each dosage unit (e.g. per 5ml etc...)
 - b) A statement of the net contents (e.g. number of dosage units, weight or volume)
- d) Any special storage conditions that may be necessary
- e) Warning and precautions that may be necessary
- f) The Date of manufacture
- g) The Date of expiry where applicable
- h) The batch or lot number assigned by the manufacturer and
- i) The Name and address of manufacturer
- j) Name and address of supplier, if supplier is not the manufacturer

- 6.2 Size of the letters of the above (f), (g), (h) and the SR Number on the outer carton should not be less than 1.5 cm.
- 6.3 Labeling of the products ordered under this range of indents, in addition to the labeling requirements stipulated in the BP/USP relevant standards, should also bear the State Logo.
- 6.4 Deleted
- 6.5 Deleted

7. IDENTIFICATION MARKS

The "State Mark" and "SR NO" made available by SPC should be embossed or imprinted in each (item) ampoule/ vial/ pack or on the affixed label. These marks should be indelible.

- 8. TERMS OF DELIVERY (Sea/Air freight)
- 8.1 All shipments should be made exclusively on vessels belonging to the Ceylon shipping Corporation or those chartered by CSC. Shipments on other vessels will be permitted in instances where vessel of the Ceylon Shipping Corporation do not call at the Port of shipment or if they are not available for time by shipment of cargo, in which event the supplier should attached a waiver certificate issued by Ceylon Shipping Corporation or their Authorized Agent in the Supplier's Country.
- 8.2 SPC may nominate Independent Competent Authorities for issue of shipment Certificate (Certificate of Quality, Quantity and Loading) cost of such certificate should be borne by the supplier
- **8.3** All items should be shipped to the destination and strictly conform to the delivery dates as per schedule I hereto marked ------.

8.4 If the supplier fails to make deliveries within the time specified by the SPC (without prejudice to the other rights of SPC resulting from breach of the contract conditions) May be written notice to the supplier terminate the right of the supplier to proceed with any or all of the remaining part of the contract as provided for in clause 9.1 hereof in addition the SPC reserves the right to purchase from other sources any or all undelivered items and to recover excess costs from the supplier.

8.5 Deleted

8.7. Delivery of all goods should be within the period indicated in the Indent, except in exceptional circumstances no extensions will be granted. Cost of such extension in any would be borne by the supplier.

8. PAYMENT

Payment will be arrange as per the terms and condition of Indian credit Line facility agreement with Government of Sri Lanka. Payment will be made in Indian Rupee equivalent to offer price in USD.

9. PERFORMANCE BOND

11.1 As security for the due and punctual performance and fulfillment of the terms of this Agreement by the satisfactory completion of the supply and delivery, for the payment of all claims to which SPC may be entitled under the provisions of this Agreement. The supplier has furnished the State Pharmaceuticals Corporation with a Bank Guarantee from a Bank approved by the SPC in the sum of United States Dollars only. (USD)

10.ARBITRATION

- 10.1 If any dispute or difference or claim shall arise between the parties as to any point in any agreement or contract arising of the invitation to Bid, or as to any matter or thing of whatsoever nature arising there-under or in connection therewith, then either party shall within 30 days give to the other, notice in writing of such dispute or difference. Such notice shall specify the matters which are in dispute. Such dispute shall be referred to a single arbitrator in case the parties agree upon one; otherwise to three arbitrators; one to be appointed by each party and the third arbitrator by the other two arbitrators. If either party shall refuse or neglect to appoint an arbitrator within twenty days after the other party shall have appointed an arbitrator and given notice thereof requiring such appointment, then the arbitrator appointed as aforesaid shall proceed to hear and determine the matters as if he were and arbitrator appointed by both parties to the dispute.
- 10.2 The decision or award of the arbitrator or arbitrators (as the case may be) shall be final and binding upon the parties and shall be a prerequisite to any proceedings in a Court of Law.

- 10.3 The arbitrator or arbitrators shall determine by whom, and in what manner, the cost of arbitration (or any party thereof) shall be borne and paid.
- 10.4 The arbitration shall be governed by the Arbitration Act. No. 11 of 1995 Laws of Sri Lanka and shall be held in Sri Lanka.
- 10.5 Performance of the contract shall continue during arbitration proceedings as far as possible.

11. LAW

11.1 The Laws of the Democratic Socialist Republic of Sri Lanka shall govern the validity, performance and enforcement of this contract.

12.INDEMNITY

- 12.1 The supplier shall at all times keep indemnified the SPC against any and all claims at any time arising on account of -
 - (a) Patent right or other rights whether from manufacturer or others, from use in Sri Lanka of the goods supplied.
 - (b) Product liability claims against SPC arising out of the goods supplied under this contract e.g. due to incorrect labeling, deviation from agreed specifications etc.

13.WARRANTY

13.1 The supplier warrants that goods supplied shall be of recent manufacture and of good quality; shall have no defect in manufacture, shall meet all the requirements of the specifications and shall in all aspects suited for the purposes intended the warranty provided by the supplier shall be relied upon and strictly enforced by SPC.

14. WARRANTY AGAINST BENEFITS

- 14.1 The supplier warrants that he/it has not given or promised to give any money or gift to any officer or employee of SPC or any Government instrumentality or employee thereof with the intent or objective of securing the contract.
- 14.2 Any violation of this warranty shall be sufficient grounds for cancellation or revocation of the contract without any claim against SPC.

15. LOCAL AGENT

17.1 Name & Address : M/s.

•

Telephone No :

E-mail :

Fax No :

16. ASSIGNMENT

16.1 Supplier shall not without the prior written consent of the SPC assign his contract or part thereof to another.

19. Deleted.

20. FORCE MAJEURE

20.1 The supplier shall not be liable for any delay or failure in making delivery of the supplies if it was due to any event which interfered with performance and was beyond the control of the supplier. However, at every time the supplier faces a situation disturbing the due performance of the obligations under this contract due to conditions beyond his/ its control he/it should write to SPC and get its approval. Approval/disapproval will be notified within Seven (7) working days of receipt of same in writing. Parties however shall endeavors to remove any obstacles to performance (when possible) and co-operate to remove the harmful effects as far as practicable.

21. NOTICE

21.1 All notices given in respect of this contract shall be deemed to be sufficiently given if sent by registered post addressed to the either party at the respective address` at the beginning hereof written.

INDENT NO :

ITEM :

SUPPLIER : M/s.

In witness whereof the official Seal and the signature of the Authorized officers of the State Pharmaceuticals Corporation of Sri Lanka was affixed hereto namely------.

MANAGER (IMPORTS / AUTHORIZED OFFICER – PHARMACETIUCALS

<u>Witnesses</u>	
Signature	Name, Address and ID No.
1	•••••••••••••••••••••••••••••••••••••••
2	

Form A Supportive documents to be submitted with the Performa Invoice. The following documents should be submitted by the importer with respect to the prospective exporter in India.

1	spective exporter in muia.	I
	Description	Remarks
01	Nature of entity: Company/ Proprietorship firm/ Others;	Specify here
02	Certificate of Incorporation (or equivalent documents of	Certified by
	constitution or association), and/or documents of	company
	registration;	secretary/ a
		director/ partner/
		lawyer.
03	IEC, PAN and GST Registration details (Copies);	Certified by
		company
		secretary/ a
		director/ partner/
		a lawyer.
04	List of Board of Directors with their complete designation	Certified by
	in case of nominee Directors;	company secretary
05	The beneficial ownership with respective shareholding	Certified by the
	and nationality of shareholders of the JV Member (in case	company secretary
	of a JV);	or a director
06	A copy (self-attested on all pages) of Power of Attorney in	Certified by the
	favour of the person who has been authorised, through an	company
	appropriate Company Board Resolution or equivalent	secretary/ a
	document, to sign on behalf of the Applicant;	director/ a
		partner/ a lawyer.
07	Financial Status & Capacity, certified by the Statutory	
	Auditors of the company/firm;	
08	In case of JV, Applicant's JV Member's Information (in the	Attach duly filled
	format attached);	form "C"
09	Details of non-performed export contracts, if any;	Specify details
10	Copy of necessary Certificates regarding safety from	Certified by the
	relevant agencies in India such as Food Safety and	~ ~
		company
	Standards Authority of India (FSSAI) in case of food items;	secretary/ a
	Standards Authority of India (FSSAI) in case of food items; Drugs Controller General of India (DCGI) in case of	secretary/ a director/ a
	Standards Authority of India (FSSAI) in case of food items; Drugs Controller General of India (DCGI) in case of medicines etc, wherever applicable;	secretary/ a director/ a partner/ a lawyer.
11	Standards Authority of India (FSSAI) in case of food items; Drugs Controller General of India (DCGI) in case of	secretary/ a director/ a partner/ a lawyer. Attach duly filled
	Standards Authority of India (FSSAI) in case of food items; Drugs Controller General of India (DCGI) in case of medicines etc, wherever applicable; Details, as mentioned in the attached questionnaire;	secretary/ a director/ a partner/ a lawyer. Attach duly filled form "B"
11 12	Standards Authority of India (FSSAI) in case of food items; Drugs Controller General of India (DCGI) in case of medicines etc, wherever applicable; Details, as mentioned in the attached questionnaire; Declaration / Affidavit to the effect that all the	secretary/ a director/ a partner/ a lawyer. Attach duly filled form "B" Attach duly filled
	Standards Authority of India (FSSAI) in case of food items; Drugs Controller General of India (DCGI) in case of medicines etc, wherever applicable; Details, as mentioned in the attached questionnaire; Declaration / Affidavit to the effect that all the information provided in the prescribed format is correct	secretary/ a director/ a partner/ a lawyer. Attach duly filled form "B"
	Standards Authority of India (FSSAI) in case of food items; Drugs Controller General of India (DCGI) in case of medicines etc, wherever applicable; Details, as mentioned in the attached questionnaire; Declaration / Affidavit to the effect that all the information provided in the prescribed format is correct and in case any figures or information given therein are	secretary/ a director/ a partner/ a lawyer. Attach duly filled form "B" Attach duly filled
	Standards Authority of India (FSSAI) in case of food items; Drugs Controller General of India (DCGI) in case of medicines etc, wherever applicable; Details, as mentioned in the attached questionnaire; Declaration / Affidavit to the effect that all the information provided in the prescribed format is correct and in case any figures or information given therein are found to be incorrect and/ or certificates/documents	secretary/ a director/ a partner/ a lawyer. Attach duly filled form "B" Attach duly filled
	Standards Authority of India (FSSAI) in case of food items; Drugs Controller General of India (DCGI) in case of medicines etc, wherever applicable; Details, as mentioned in the attached questionnaire; Declaration / Affidavit to the effect that all the information provided in the prescribed format is correct and in case any figures or information given therein are found to be incorrect and/ or certificates/documents provided in support of the relevant information entered	secretary/ a director/ a partner/ a lawyer. Attach duly filled form "B" Attach duly filled
	Standards Authority of India (FSSAI) in case of food items; Drugs Controller General of India (DCGI) in case of medicines etc, wherever applicable; Details, as mentioned in the attached questionnaire; Declaration / Affidavit to the effect that all the information provided in the prescribed format is correct and in case any figures or information given therein are found to be incorrect and/ or certificates/documents provided in support of the relevant information entered therein are found to be fabricated, the contract will not be	secretary/ a director/ a partner/ a lawyer. Attach duly filled form "B" Attach duly filled
	Standards Authority of India (FSSAI) in case of food items; Drugs Controller General of India (DCGI) in case of medicines etc, wherever applicable; Details, as mentioned in the attached questionnaire; Declaration / Affidavit to the effect that all the information provided in the prescribed format is correct and in case any figures or information given therein are found to be incorrect and/ or certificates/documents provided in support of the relevant information entered therein are found to be fabricated, the contract will not be considered for inclusion under the credit facility (in the	secretary/ a director/ a partner/ a lawyer. Attach duly filled form "B" Attach duly filled
12	Standards Authority of India (FSSAI) in case of food items; Drugs Controller General of India (DCGI) in case of medicines etc, wherever applicable; Details, as mentioned in the attached questionnaire; Declaration / Affidavit to the effect that all the information provided in the prescribed format is correct and in case any figures or information given therein are found to be incorrect and/ or certificates/documents provided in support of the relevant information entered therein are found to be fabricated, the contract will not be considered for inclusion under the credit facility (in the format attached).	secretary/ a director/ a partner/ a lawyer. Attach duly filled form "B" Attach duly filled form "E"
	Standards Authority of India (FSSAI) in case of food items; Drugs Controller General of India (DCGI) in case of medicines etc, wherever applicable; Details, as mentioned in the attached questionnaire; Declaration / Affidavit to the effect that all the information provided in the prescribed format is correct and in case any figures or information given therein are found to be incorrect and/ or certificates/documents provided in support of the relevant information entered therein are found to be fabricated, the contract will not be considered for inclusion under the credit facility (in the	secretary/ a director/ a partner/ a lawyer. Attach duly filled form "B" Attach duly filled

Format of questionnaire

S.No.	Information sought	Response
1.	Has your firm been suspended or debarred by any Multilateral Agency, or any government or government procuring entity, or a UN agency? If Yes, provide details, including date of reinstatement, if applicable. Attach additional sheets, if needed.	Yes/No
2.	Has your firm's account been classified as Non-Performing Asset (NPA) with any Bank/FI or your companies/ promoters/ directors appear in Reserve Bank of India (RBI) Caution List, RBI Wilful Defaulter List (Suit filed as well as non-suit filed), Credit Information Bureau India Ltd (CIBIL) Defaulter List or any other negative list of the Indian central or state government agencies, updated from time to time? If yes, please provide details in a separate sheet, as necessary.	Yes/No
3.	Has your firm/organization ever filed or petitioned for bankruptcy? If Yes, furnish details of the case including filing date and current status.	Yes/No
4.	Has your firm/ any JV partner been penalized for delay in contractual performance in the last 5 years prior to Application submission deadline. If yes, please provide details in a separate sheet, as necessary.	Yes/No
5.	Has there been a termination of your contract for nonperformance in the last 5 years prior to the month preceding the month of Application Submission Deadline? If yes, please describe in detail in a separate sheet, as necessary.	Yes/No
6.	Is there any pending litigation against the firm, involving the Government of India, State Governments or any Government agencies, on matters relating to financial impropriety, money laundering and/or tax evasion? If yes, please provide additional details.	Yes/No

The undersigned declares that all information, statements and description contained in this document is correct in all respects and complete to the best of my knowledge and belief.

Signature
Name of the signatory
Company Name

Note: - In case any figures or information given therein are found to be incorrect and/ or certificates/documents provided in support of the relevant information entered therein are found to be fabricated, the contract will not be considered for inclusion under the credit facility.

Form C

Applicant's JV Member's Information Form

S.No.	Details required
1.	Applicant Name:
2.	Applicant's JV Member's name:
3.	Applicants JV Member's country of registration:
4.	Applicants JV Member's date of constitution:
5.	Applicants JV Member's legal address registered in India:
6.	Applicants JV Member's authorized representative
	information-
	Name:
	Address:
	Telephone/Fax No:
	Email address:

Form D

(Exporter's Bank letter head)	(data)
(Importer's Bank and Address)	(date)
Dear Sir	
Agreement on Receiving Payments in Indian Rupees (I	INR)
Name of Exporter and Address	
Performa Invoice No	
Date	
Value in USD	
I do hereby agree to receive the payment for the afore supplied to	(importers name and address), in
the Government of India and the Government of Sri La	
This letter is issued on the request of the Exporter	ma.
(Signature of Authorized Officer	(Date and Seal) of
the Exporter's Bank and designation)	(Date allu Seal) ol
the Exporter's Dank and designation;	

Form E

AFFIDAVIT

The undersigned declares that all information, statements and description contained in the Application is correct in all respects and complete to the best of our knowledge and belief.

We understand that in case any figures or information given therein are found to be incorrect and/ or certificates/documents provided in support of the relevant information entered therein are found to be fabricated, the contract will not be considered for inclusion under the credit facility

Name of firm/company:
Signature(s) of authorized representative(s) of the Applicant:
Name of signatory:
In the capacity of:
Address:
Date:

7	IEC CODE OF THE EXPORTER				
MATION	ACCOU NT NUMB ER				
BANK INFORMATION	AD BANK '				
а	SOD				
	BAN K K NA C				
	VESSEL NAME/IM O NO.				
	COUNTRY OF ORIGIN (EXPORTER)				
	SHIPM ENT TO (PORT)				
	SHIPMEN T T O (COUNTR Y)				
	SHIPMEN T FROM (PORT)				
SIIS	SHIPMENT FROM (country)				
DETA	SHIP AENT DATE				
GOODS DETAILS	CONTRY OF ORIGIN OF I				
	DESCRIPTIO HSBILL NO/AMOUNT PAYABLE CONTRY OF SHIP SHIPMENT SHIPMENT TROM T FROM T FROM (COUNTRY OF EXPORTER E NO INVOICE CHARGES GOODS DATE (COUNTRY) (PORT) (FORT) (EXPORTER) O NO. ME DETAILS ER EXPORTER				
	AMOUN T OF INVOICE				
	BILL NO/ INVOICE NO				
	SCOD SCOD				
	DESCRIPTIC N OF GOOD: EXPORTEI				
ADDR					
EXPORT ADDR ER ESS NAME					

MSD Order List No :2022/SPC/X/R/P/00312

	SR	ITEM DESCRIPTION	QUANTITY		DELIVERY SCHEDULE
1	01206501	Megestrol acetate tablet 40mg	7,500	TAB	4,000 Tabs – 01 st April 2022
		Megestrol Tablets BP OR Megestrol Acetate Tablets USP Each tablet to contain 40mg of Megestrol Acetate BP/USP			3,500 Tabs – 01 st Oct. 2022
		Note: 01.The shelf life of the product should be minimum of 24 months Pack Size: 01 TAB X 100 BOX			

MSD Order List No :2022/SPC/X/R/P/00313

	SR	ITEM DESCRIPTION	QUANTITY		DELIVERY SCHEDULE
2	00201401	Esmolol HCl Inj. 100mg/10ml Esmolol Hydrochloride Injection 100mg in 10ml Each 10ml vial to contain 100mg of Esmolol Hydrochloride for intravenous infusion. Note: 1. The injection should be stable for a minimum of 2 years when stored at a temperature range of 28'C-32'C 2. Each ampoule should be labelled accordingly.	100	VIAL	50 vials – 01 st April 2022 50 vials – 28 th July 2022
3	00201702	Pack Size: 01 VIAL X 10 PACK Hydralazine HCl Inj. 20mg/1ml Hydralazine Injection BP/USP 20mg. Each 1ml ampoule to contain 20mg of Hydralazine Hydrochloride BP/USP for intravenous infusion (Not in dextrose) slow intravenous injection and intramuscular injection. Note: 1. This injection should be stable for a minimum of 02 years when stored at a temperature range of 28'C-32'C 2. Each ampoule should be labelled accordingly. Pack Size: 01 AMP X 10 PACK	2,500	AMP	1,250 Amps – 16 th May 2022 1,250 Amps – 15 th July 2022

MSD Order List No :2022/SPC/X/C/P/00311

	SR	ITEM DESCRIPTION	QUANTITY		DELIVERY SCHEDULE
4	01206402	Thalidomide capsules 50mg Thalidomide capsule USP 50mg Each capsule to contain 50mg of Thalidomide USP Note: 01.The shelf life of the product should be minimum of 24 months Pack Size: 01 CAP X 100 BOX	12,000	CAPS	12,000 Caps – 01 st Aug. 2022
5	01201703	Cytarabine injection1g in 10ml vial Cytarabine Injection BP 1g/10ml, (Not for intrathecal use) Each 10ml vial to contain 1g of Cytarabine BP in water for injection BP/USP OR Cytarabine for Injection USP 1g, (Not for intrathecal use) Each vial to contain 1g of Cytarabine BP/USP as sterile dry powder for reconstitution with water for injection BP/USP before use for intravenous and subcutaneous use Note: 1.This injection should be stable for 24 months when stored at a temperature within 28'C-32'C. 2.Each vial should be labelled accordingly Pack Size: 01 VIAL BOX	6,000	VIALS	3,000 Vials – 01 st April 2022 3,000 Vials – 01 st Oct. 2022

MSD Order List No :2022/SPC/X/C/P/00297

	SR	ITEM DESCRIPTION	QUAI	NTITY	DELIVERY SCHEDULE
6	00704001	Danazol cap. 100mg Danazole Capsule USP 100mg. Each capsule to contain 100mg of Danazole USP. Note: 01.The shelf life of the product should be minimum of 24 months. Pack Size: 01 CAP X 10 PACK	100,000	CAPS	50,000 Caps – 30 th April 2022 25,000 Caps – 01 st Sep. 2022 25,000 Caps – 30 th Nov. 2022

7	00704502	Triamcinolone acetonide inj. (Preservative Free) 40mg/ml Triamcinolone acetonide (preservative free) injection 40mg in 1ml vial. Each vial to contain 40mg of Triamcinolone acetonide BP as sterile suspension in very fine particles, in water for injections containing suitable dispersing agents for intra- articular or intramuscular use. OR Each vial to contain 40mg of Triamcinolone acetonide USP, as sterile suspension in a suitable aqueous medium for intra-articular or intramuscular use. Note: 1. Product should be protected from light. 2. Each vial should be labeled accordingly. Pack Size: 01 VIAL X 10 PACK	1,500	VIALS	750 Vials – 30 th April 2022 750 Vials – 01 st Sep. 2022
8	00705501	Diazoxide tablet 50mg Diazoxide tablets 50mg Each tablet to contain 50mg of Diazoxide BP/USP Note: 01.The shelf life of the product should be minimum of 24 months. 02.The product should be protected from light. Pack Size: 01 TAB X 10 BOX	8,500	TABS	4,500 Tabs – 30 th April 2022 4,000 Tabs – 01 st Sep. 2022

MSD Order List No :2022/SPC/X/C/P/00315

	SR	ITEM DESCRIPTION	QUAN	ITITY	DELIVERY SCHEDULE
0					
9	00201602	Metoprolol Tartrate inj. 5mg in 5ml	800	AMPS	400 Amps –

		Metoprolol Tartrate injection 1mg/ml,5ml			01 st April 2022
		ampoule Metoprolol Tartrate injection USP 1mg/ml,5ml ampoule			400 Amps – 15 th June 2022
		Each 5ml ampoule to contain a sterile solution of Metoprolol Tartrate USP 5mg and Sodium chloride USP 45mg as a tonicity adjusting agent in Water for injection BP/USP OR Metoprolol injection BP,1mg/ml,5ml ampoule			
		Each 5ml ampoule to contain a sterile solution of Metoprolol Tartrate BP 5mg in Water for Injection BP/USP.			
		Note: 1. The injection should comply with the			
		requirements stated under Parenteral			
		Preparations and it should be preserve in single-dose, light -resistant ampoules.			
		2. The injection should be stable for 24 months when stored at a temperature range of 28 C-			
		32'C			
10	00205001	Pack Size: 01 AMP X 10 PACK	200	DECV	100 DE C
10	00205001	Fondaparinux sod. Inj. 2.5mg/0.5ml	200	PFSY	100 PF. Syr – 01 st April 2022
		Fondaparinux sodium 2.5mg in 0.5ml solution for injection			100 PF. Syr –
		Each single dose,0.5ml prefilled syringe to			01 st July 2022
		contain 2.5 mg of fondaparinux sodium in injectable solution for			
		subcutaneous use.			
		Note:			
		1.The produt should be stable for 24 months			
		when stored under storage condition			
		stipulated by the manuifacturer. Pack Size: 01 PFSY			
11	00207101	Milrinone Lactate Inj.10mg/10ml amp	1,000	AMPS	1,000 Amps –
		Milrinone Lactate Injection 10mg/10ml			15 th Aug. 2022
		ampoule			
		Each 10ml ampoule to contain 10mg of Milrinone Lactate for intravenous			
		injection.			
		Note;			
		1.The injection should be stable for a minimum of 02			
		years when stored at a temperature range of			
		28'C-32'C			
		2.Each ampoule should be labelled accordingly.			

			Pack Size: 01 AMP X 10 PACK			
Ī	12	00208601	Metolazone tablet 5mg	200,000	TABS	100,000 Tabs –
						01 st April 2022
			Metolazone tablets USP 5mg Each tablet to contain 5mg of Metolazone USP			100,000 Tabs – 01 st June 2022
			Note: 01.The shelf life of the product should be minimum of 24 months. 02.The product should be kept in tight, light resistant containers, and store below 30'C.			
			Pack Size: 01 TAB X 10 PACK			

MSD Order List No :2022/SPC/X/R/P/00293

	SR	ITEM DESCRIPTION	QUAI	NTITY	DELIVERY SCHEDULE
13	01600201	Acetylcysteine injection 2g/10ml amp Acetylcysteine Injection BP 2g/ 10ml Each 10ml amber colourd ampoule to contain 2g of Acetylcysteine BP for intravenous injection/infusion. Note: 1.This injection should be stabled for a minimum of 24 months when stored at a temperature range of 28'C-32'C 2. To be protected from light 3. Each ampoule should be labelled accordingly.	96,000	AMPS	48,000 Amps – 30 th April 2022 48,000 Amps – 30 th Sep. 2022
14	00204201	Pack Size: 01 AMP X 10 PACK Ephedrine Inj. 30mg/1ml amp Ephedrine injection BP 30mg/ml Each 1ml amber coloured ampoule to contain 30mg of Ephedrine Hydrochloride BP for intravenous, subcutaneous and intramuscular injection. or Ephedrine Sulphate injection USP 30mg/ml Each 1ml amber coloured ampoule to contain 30mg of Ephedrine Sulphate USP for intravenous, subcutaneous and intramuscular injection. Note: 1.This injection should be stable for minimum of 24 months when stored at a temperature	145,000	AMPS	75,000 Amps – 30 th April 2022 70,000 Amps – 30 th Sep. 2022

		range of 28'C-32'C 2.Each ampoule should be labelled accordingly. 3. Ampoule should be easy breakable with one-point cut (OPC) or color breaking (CBR) or both Pack Size: 01 AMP X 10 PACK			
15	00500601	Aminophylline Inj. 250mg/10ml Aminophylline Injection BP/USP,250mg in 10ml Each 10ml ampoule to contain 250mg of Aminophylline BP/USP for deep intramuscular injection and intravenous infusion(in water for injection BP/USP,free from Carbondioxide) Note; 1.This injection should be stable for a minimum of 02 years when stored at a temperature range of 28'C-32'C. 2.The product should be packed in a light-resistant boxes/containers. 3.Each ampoule should be labelled accordingly. Pack Size: 01 AMP X 10 PACK	7,500	AMPS	7,500 Amps – 30 th Oct. 2022
16	00500403	Ipratropium Br. Resp. solution 0.25mg/1ml, 15ml Ipratropium Bromide respiratory solution, 250mcg in 1ml, 15ml. Each 15ml vial to contain 250mcg/ml of Ipratropium Bromide BP(2000) in suitable base for use in nebuliser. Note: 1) Each vial should be labelled accordingly. Pack Size: 01 VIAL X 10 PACK	120,000	VIALS	60,000 Vials – 30 th April 2022 60,000 Vials – 30 th Sep. 2022
17	01601001	Pralidoxime chloride inj.1g/20ml Pralidoxime Chloride for injection USP 1g in 20ml Each 20ml vial to contain 1g of sterile Pralidoxime Chloride USP for reconstitution with water for injection BP/USP suitable for subcutaneous, intramuscular and intravenous injection. Note: 1.This injection should be stable for minimum of 24 months when stored at a temperature range of 28'C-32'C 2.Each ampoule should be labelled accordingly Pack Size: 01 AMP X 10 PACK	24,000	AMPS	12,000 Amps – 30 th April 2022 12,000 Amps – 30 th Sep 2022

MSD Order List No :2022/SPC/X/R/P/00296

	SR	ITEM DESCRIPTION	QUANTITY		DELIVERY SCHEDULE
18	00701501	Hydrocortisone tablet 5mg	100,000	TABS	50,000 Tabs –
		Hydrocortisone Tablets USP 5mg Each tablet to contain 5mg of Hydrocortisone USP. Note: 01.The shelf life of the product should be minimum of 24 months.			30 th April 2022 50,000 Tabs – 01 st Sep. 2022
		Pack Size: 01 TAB X 10 PACK			
19	00702701		8,500	AMPS	4,500 Amps –
		Testosterone enanthate Inj.250mg/1ml Testosterone enanthate Injection USP 250mg in 1ml Ampoule. Each 1ml ampoule to contain 250mg of Testosterone enanthate USP in suitable vegetable oil for slow intramuscular injection Note: 1.The Injection should be stable for a minimum of 24 months when stored at a temperature range of 28'C-32'C 2.Each ampoule should be labeled accordingly. Pack Size: 1 AMP X 10 PACK			30 th April 2022 4,000 Amps – 01 st Sep. 2022
	00706401	Testosterone undecanoate Inj.250mg /1ml ,4ml vial Testosterone undecanoate Injection (oily) 250mg/ml in 4ml vial Each 4ml vial to contain 1000mg of Testosterone Undecanoate corresponding to 631.5 mg Testosterone for intramuscular injection. Note: 1.This product should be stable for a minimum of 24 months when stored at a temperature range of 28'C-32'C. 2.Each vial should be labeled accordingly Pack Size: 1 VIAL X 10 PACL	1,000	VIALS	500 Vials – 30 th April 2022 500 Vials – 01 st Sep. 2022
	01300302	Dinoprostone vaginal gel 1mg/2.5ml tube	6,000	TUBES	3,000 Tubes –

					30 th April 2022
		Dinoprostone vaginal gel 400mcg/ml ,2.5ml Tube			3,000 Tubes –
		Each tube to contain 400mcg/ml of Dinoprostone BP/USP. Note:			01 st Sep. 2022
		01.The shelf life of the product should be minimum of 24 months.			
		Pack Size: 1 TUBE X 10 PACK			
22	01301601	Terazosin tablet 1mg	3,500	TABS	2,000 Tabs –
		-			30 th April 2022
		Terazosin tablet 1mg Each tablet to contain 1mg of Terazosin USP Note:			1,500 Tabs – 01 st Sep. 2022
		01.The shelf life of the product should be minimum of 24 months			
		Pack Size: 1 TAB X 10 PACK			
23	00702101	Dydrogesterone tablet. 10mg	100,000	TABS	50,000 Tabs –
		Dydrogesterone tablet 10mg BP			30 th April 2022
		Each tablet to contain 10mg of Dydrogesterone BP			50,000 Tabs – 01 st Sep. 2022
		Note: 1.Tablets should be protected from light. 2.The shelf life of the product should be minimum of 24 months.			
		Pack Size : 1 TAB X 10 PACK			
24	00703801	Bromocriptine tablet 2.5mg	50,000	TABS	25,000 Tabs – 30 th April 2022
		Bromocriptine Tablets BP, 2.5mg Each tablet to contain Bromocriptine Mesylate BP equivalent to 2.5mg of Bromocriptine. OR			25,000 Tabs – 01 st Sep. 2022
		Bromocriptine Mesylate Tablets USP, 2.5mg Each tablet to contain Bromocriptine Mesylate USP equivalent to 2.5mg of Bromocriptine. Note: 01.The shelf life of the product should be			
		minimum of 24 months.			
		Pack Size : 1 TAB X 10 PACK			
25	00704501	Triamcinolone acetonide Inj. 40mg/ml	2,000	VIALS	1,000 Vials -

					30 th April 2022
					1,000 vials – 01 st Sep. 2022
		Triamcinolone acetonide injection BP 40mg in 1ml vial.			
		Each vial to contain 40mg of Triamcinolone acetonide BP as sterile suspension in very fine			
		particles, in water for injections containing suitable dispersing agents			
		for intra- articular or intramuscular use. OR			
		Triamcinolone acetonide injection USP 40mg in 1ml Vial.			
		Each vial to contain 40mg of Triamcinolone acetonide USP,as sterile suspension in a			
		suitable aqueous medium for intra-articular or intramuscular use.			
		Note:			
		Injections should be protected from light.			
		2. Each vial should be labeled accordingly.			
26	00701902	Pack Size: 01 VIAL PACK	20.000	TABS	10,000 Tabs –
20	00/01902	Conjugated Estrogen tablet 625mcg	20,000	TABS	30 th April 2022
		Conjugated Estrogen Tablets USP 625mcg Each tablet to contain 625mcg of Conjugated Estrogen USP.			10,000 Tabs – 01 st Sep. 2022
		Note: 01.The shelf life of the product should be minimum of 24 months.			
		Pack Size: 01 TAB X 10 PACK			
27	00703701	Zoledronic acid Injection 4mg/5ml	7,000	VIALS	7,000 Vials – 01 st June 2022
		Zoledronic acid concentrate for intravenous infusion 4mg in 5ml vial Each 5ml vial to contain 4mg of Zoledronic acid for intravenous infusion.			32 330 2022
		Note:			
		1.The Injection should be stable for minimum of 24			
		months when stored at a temperature range of 28'C-32'C			
		2. Each vial should be labelled accordingly			
		Pack Size : 01 VIUAL PACK			

MSD Order List No :2022/SPC/X/R/P/00306

	SR	ITEM DESCRIPTION	QUAI	NTITY	DELIVERY SCHEDULE
28	01200401	Ifosfamide 1g vial + Mesna 100mgin 1ml, 3 amps in one set	7,500	SETS	4,000 Sets – 01 st April 2022
		 (A) Sterile Ifosfamide injection USP 1g vial Each vial to contain 1g of Ifosfamide USP as sterile dry powder for reconstitution with water for injection BP/USP before use for intravenous injection or intravenous infusion in the correct (1:3) combination with Mesna for injection. (B) Mesna for injection 100mg in 1ml Each 1ml Vial to contain 100mg of Mesna for intravenous injection or intravenous infusion 			3,500 Tabs – 01 st Oct. 2022
		Pack: 1 vial of A and 3 vials of B in a set. Note: 1.These injections should be stable for a minimum of 24 months when stored under manufacturer's conditions. 2.Each vial should be labelled accordingly. Pack Size: 01 SET IN A BOX			
29	01202701	Etoposide capsule 100mg Etoposide Capsules USP/BP 100mg Each capsule to contain 100mg of Etoposide USP/BP. Note: 01.The shelf life of the product should be minimum of 24 months Pack Size: 01 CAP X 100 BOX	4,800	CAPS	2,400 Caps – 01 st April 2022 2,400 Caps – 01 st Sep. 2022
30	01202703	Etoposide Capsules 50mg Etoposide Capsules USP 50mg Each capsule to contain 50mg of Etoposide USP. Note: 01. The shelf life of the product should be minimum of 24 months Pack Size: 01 CAP X 100 BOX	1,200	CAPS	600 Caps – 01 st April 2022 600 Caps – 01 st Oct. 2022
31	01202801	Leucovorin Tablets 15mg (Folinic acid)	12,000	TABS	12,000 Tabs –

		Leucovorin Calcium (Folinic Acid)Tablets USP,			01 st April 2022
		15mg Each tablet to contain 15mg of Leucovorin			12,000 Tabs –
		Calcium USP.			01 st Oct. 2022
		Note:			
		01.The shelf life of the product should be			
		minimum of 24 months			
22	04202502	Pack Size: 01 TAB X 100 BOX	25.000	TARC	42.000 Tala
32	01203502	Hydroxyurea (Hydroxycarbamide)tab/cap 100mg	25,000	TABS	13,000 Tabs – 01 st April 2022
		Toomg			01 April 2022
		Hydroxyurea(Hydroxy carbamide) tablet/			12,000 Tabs –
		capsule 100mg			01 st Oct. 2022
		Each tablet/capsule to contain 100 mg of			
		Hydroxyurea /Hydroxycarbamide BP/USP			
		Notes			
		Note: 01.The shelf life of the product should be			
		minimum of 24 months			
		Pack Size: 01 TAB X 100 BOX			
33	01203701	Cisplatin injection 10mg vial	500	VIALS	500 Vials – 01 st
					Aug. 2022
		Cisplatin injection BP, 10mg/10ml			
		Each 10ml vial to contain 10mg of Cisplatin BP			
		in water for injection BP/USP			
		for intravenous injection. OR			
		Cisplatin for injection BP/USP, 10mg			
		Each vial to contain 10mg Cisplatin BP/USP as			
		sterile dry powder for			
		reconstitution with water for injection BP/USP,			
		before use for intravenous			
		injection Note:			
		1.This injection should be stable for a minimum			
		of 24			
		months when stored under temperature			
		range of			
		15 C - 30 C. Protect from light.			
		2.Each vial should be labelled accordingly.			
34	01204403	Pack Size: 01 VIAL BOX	250,000	CAPS	125,000 Caps –
)4	01204403	Imatinib mesylate capsules/tablets 400mg Imatinib mesilate Capsule 400mg	230,000	CAPS	01 st April 2022
		Each capsule to contain 400mg of Imatinib			
		mesylate BP			125,000 Caps –
		OR			01 st Oct. 2022
		Imatinib mesilate tablet 400mg			
		Each tablet to contain 400mg of Imatinib			
		mesylate BP			

	Note: 01.The shelf life of the product should be minimum of 24 months Pack Size: 01 CAP X 100 BOX			
01205001	Irinotecan injection 40mg/2ml	3,000	VIALS	1,500 Vials –
	Irinotecan hydrochloride trihydrate Injection 40mg in 2ml Vial Each 2ml vial to contain Irinotecan hydrochloride trihydrate equivalant to 40mg of Irinotecan hydrochloride for intravenous use.			01 st April 2022 1,500 Vials – 01 st Oct. 2022
	Note:			
	1. The injection should be stable for a minimum of 24 months when stored at a temperature range of 28 'C-32 'C			
01206701			TARS	1,000,000 Tabs
01200701	Anastrozole Tablet 1mg	2,000,000	17.156	- 01 st April 2022
	Lacif Tablet to contain Ting of Anastrosofe			1,000,000 Tabs
	Note:			– 01 st Oct. 2022
	01.The shelf life of the product should be			
01204401		600 000	CADS	300,000 Caps –
01204401	Imatinib mesilate Capsules 100mg Each capsule to contain 100mg of Imatinib mesilate. Note: 01.The shelf life of the product should be	000,000	CAIS	300,000 Caps – 01 st Oct. 2022
04207204	Pack Size: 01 CAP X 100 BOX	42.000		7.000 lavalant
0120/301		13,000	IMPLANT	7,000 Implant – 01 st April 2022
				6,000 Implant – 01 st Sep. 2022
	Goserelin acetate implant 3.6mg			
	Goserelin Acetate 3.6mg implant in syringe applicator. Each implant to contain Goseraline Acetate Ph Eur 3.6mg for subcutaneous use.			
	01205001	Pack Size : 01 CAP X 100 BOX 1rinotecan injection 40mg/2ml Irinotecan hydrochloride trihydrate Injection 40mg in 2ml Vial Each 2ml vial to contain Irinotecan hydrochloride trihydrate equivalant to 40mg of Irinotecan hydrochloride for intravenous use. Note: 1.The injection should be stable for a minimum of 24 months when stored at a temperature range of 28'C-32'C 2.Each vial should be labelled accordingly. Pack Size : 01 VIAL X 01 BOX 01206701 Anastrozole tablet 1mg Anastrozole Tablet 1mg Each Tablet to contain 1mg of Anastrosole Note: 01.The shelf life of the product should be minimum of 24 months Pack Size : 01 TAB X 100 BOX 01204401 Imatinib mesilate Capsules 100mg Each capsule to contain 100mg of Imatinib mesilate. Note: 01.The shelf life of the product should be minimum of 24 months Pack Size : 01 CAP X 100 BOX 01207301 Goserelin acetate implant 3.6mg Goserelin Acetate 3.6mg implant in syringe applicator. Each implant to contain Goseraline Acetate Ph	Pack Size : 01 CAP X 100 BOX 01205001	Pack Size : 01 CAP X 100 BOX 1rinotecan injection 40mg/zml 1rinotecan hydrochloride trihydrate Injection 40mg in 2ml Vial Each 2ml Vial to contain Irinotecan hydrochloride trihydrate equivalant to 40mg of Irinotecan hydrochloride for intravenous use. Note: 1. The injection should be stable for a minimum of 24 months when stored at a temperature range of 28°C-32°C 2. Each vial should be labelled accordingly. Pack Size : 01 VIAL X 01 BOX 01206701 Note: 01. The shelf life of the product should be minimum of 24 months Pack Size : 01 TAB X 100 BOX 01204401 Imatinib mesilate Capsules 100mg Each capsule to contain 100mg of Imatinib mesilate. Note: 01. The shelf life of the product should be minimum of 24 months Pack Size : 01 CAP X 100 BOX 01207301 Goserelin acetate implant 3.6mg Goserelin Acetate 3.6mg implant in syringe applicator. Each implant to contain Goseraline Acetate Ph Eur 3.6mg for subcutaneous use.

39	01202101	1.The product should be stable for a minimum of 24 months when stored below 25'C. 2.The product should be protected from light. 3.Each implant should be labelled accordingly. Pack Size: 01 IMPL X BOX Mercaptopurine tablet 50mg Mercaptopurine Tablets BP/USP 50mg Each tablet to contain 50mg of Mercaptopurine BP/USP Note: 01.The shelf life of the product should be minimum of 24 months Pack Size: 01 TAB X 100 BOX	150,000	TABS	80,000 Tabs – 01 st April 2022 70,000 Tabs – 01 st Oct. 2022
40	01206401	Thalidomide capsule 100mg Thalidomide Capsule USP 100mg Each capsule to contain 100mg of Thalidomide USP Note: 01.The shelf life of the product should be minimum of 24 months Pack Size: 01 CAP X 100 BOX	100,000	CAPS	100,000 Tabs – 01 st Oct. 2022
41	01200304	Cyclophosphamide Inj. 1 g vial Cyclophosphamide for injection BP, 1g Each vial to contain Cyclophosphamide BP equivalent to 1g of anhydrous Cyclophosphamide as sterile, dry powder for reconstituiton with water for injection BP/USP before use, for intravenous injection. OR Cyclophosphamide for injection USP,1g Each vial to contain Cyclophosphamide USP equivalent to 1g of anhydrous Cyclophosphamide as sterile, dry powder for reconstituiton with water for injection BP/USP before use, for intravenous injection. Note; 1. This injection should be stable for a minimum of 24 months when stored a temperature range of 28'C-32'C 2. Each vial should be labeled accordingly. Pack Size: 01 VIAL X 01 BOX	6,000	VIALS	6,000 Vials – 01 st Oct. 2022
42	01200801	Bleomycin sulphate injection 15 000 units vial	500	VIALS	500 Vial – 01 st Nov. 2022

43	01203803	Bleomycin Sulfate for injection BP/USP 15000 units. Each vial to contain Bleomycin Sulfate USP equivalent to 15000 units of Bleomycin as dry powder for reconstitution before use for subcutaneous, intramuscular, intravenous and intra-arterial injection OR Sterile Bleomycin Hydrochloride for injection JP, 15000 units. Each vial to contain Bleomycin Hydrochloride JP equivalent to 15000 units of Bleomycin as dry powder for reconstitution before use for subcutaneous, intramuscular, intravenous and intra-arterial injection. Note: 1. This injection should be stable for a minimum of 24 months when stored at a temperature range of 28'C - 32'C. 2. Each vial should be labelled accordingly. Pack Size: 01 VIAL X 01 BOX Oxaliplatin injection 100mg vial	10,000	VIALS	10,000 Vials —
		Oxaliplatin for injection 100mg as liophilized powder Each vial to contain 100mg of sterile, preservative free lyophylized reconstitution powder of Oxaliplatin for intravenous injection. OR Oxaliplatin injection 100mg in 20ml vial Each 20ml vial to contain sterile, concentrated solution of 5mg /1ml Oxaliplatin in water for injection BP/USP, suitable for intravenous infusion after dilution. Note; 1.The preparation should be stable for minimum of 24 months when stored under storage condition specified by the manufacturer. 2.Each vial should be lablled accordingly			01 st Aug. 2022
44	01207001	Pack Size: 01 VIAL X 01 BOX Bicalutamide tablet 50mg	250,000	TABS	250,000 Tabs –
	<u> </u>	2.00.00011100 000100 001110	l		1

					01 st Jul. 2022
		Bicalutamide tablets 50mg Each tablet to contain 50mg of Bicalutamide.			
		Note: 01.The shelf life of the product should be minimum of 24 months			
45	01201202	Pack Size: 01 TAB X 100 BOX	1 000	VIALC	1.000 \/;ala
45	01201202	Epirubicin hydrochloride Inj.50 mg vial	1,000	VIALS	1,000 Vials – 01 st Dec. 2022
		Epirubicin Hydrochloride for injection 50mg vials. Each vial to contain 50mg of Epirubicin Hydrochloride (CAS-56390-09-01) as sterile dry powder for reconstitution with water for injection BP/USP before use for intravenous infusion OR Epirubicin Hydrochloride injection 50mg/25ml Each 25ml vial to contain 50mg of Epirubicin Hydrochloride (CAS-56390-09-1) in a suitable vehicle for intravenous infusion. Note: 1. This injection should be stable for a minimum of 24 months when stored within a temperature range of 2'C - 8'C 2. Each vial should be packed in light resistant			
		box.			
		3. Each vial should be labelled accordingly			
		Pack Size : 01 VIAL X01 BOX			
46	01206302	Lenalidomide capsule 10mg	50,000	CAPS	50,000 Caps – 01 st Jul. 2022
		Lenalidomide capsules 10mg Each capsule to contain Lenalidomide 10mg Note: 01.The shelf life of the product should be minimum of 24 months Pack Size: 01 CAP X 100 BOX			
47	01200901	Actinomycin D inj. 500mcg vial	750	VIALS	750 Vials –
			I	1	L

					01 st Jul. 2022
		Dactinomycin for injection USP (Actinomycin D), 500mcg vial Each vial to contain 500mcg of Dactinomycin as sterile dry powder for reconstitution before use for intravenous use. Note: 1. This injection should be stable for a minimum of 24 months when stored at a temperature range of 28'C - 32'C 2. Each vial should be labelled accordingly Pack Size: 01 VIAL X 10 BOX			
48	01205002	Irinotecan injection 100mg/5ml	3,750	VIALS	3,750 Vials –
		Irinotecan hydrochloride trihydrate Injection 100mg in 5ml Vial Each 5ml vial to contain Irinotecan hydrochloride trihydrate equivalant to 100mg of Irinotecan hydrochloride for intravenous use.			01 st May 2022
		Note: 1. The injection should be stable for a minimum of 24 months when stored at a temperature range of 28'C-32'C 2. Each vial should be labelled accordingly. Pack Size: 01 VIAL X BOX			
49	01201904	Fluorouracil inj. 1g, 20ml vial Fluorouracil injection BP/USP 1g/20ml vial Each 20ml amber coloured vial to contain Fluorouracil Sodium equivalent to 1g of Fluorouracil BP/USP for intravenous injection, intravenous infusion and intra-arterial infusion. Note: 1. This injection should be stable for a minimum of 24 months when stored within temperature of 15'C - 25'C 2. Each vial should be labelled accordingly Pack Size: 01 VIAL X 01 BOX	9,000	VIALS	9,000 Vials – 01 st Oct. 2022
	01203801	Oxaliplatin injection 50mgvial	1,800	VIALS	1,800 Vials –

					01 st June 2022
		Oxaliplatin for injection 50mg as lyophilized powder Each vial to contain 50mg of sterile, preservative free lyophylized reconstitution powder of Oxaliplatin for intravenous injection. OR Oxaliplatin injection 50mg in 10ml vial Each 10ml vial to contain sterile, concentrated solution of 5mg /1ml Oxaliplatin in water for injection BP/USP, suitable for intravenous infusion after dilution. Note; 1.The preparation should be stable for minimum of 24 months when stored under storage condition specified by the manufacturer. 2.Each vial should be lablled accordingly Pack Size: 01 VIAL BOX			
51	01203602	Carboplatin inj. 450mg/45ml vial	11,000	VIAL	11,000 Vials –
		Carboplatin Injection BP,450mg Each 45ml vial to contain 450mg of Carboplatin BP in water for injection BP/USP for intravenous use. Note: 1.This injection should be stable for a minimum of 24 months when stored under manufacturer's conditions. 2.Each vial should be labeled accordingly Pack Size: 01 VIAL BOX			01 st Jul. 2022
52	01202202		1,750	VIAL	1,750 Vials – 01 st Aug. 2022
		Methotrexate injection 50mg/2ml vial			

		Methotrexate injection BP/USP 50mg/2ml vial Each 2ml vial to contain Methotrexate Sodium BP/USP equivalent to 25mg /ml Methotrexate BP in water for injection BP/USP containing Sodium salt for intramuscular, intravenous and intra-arterial use. OR Methotrexate for injection USP 50mg Each vial to contain Methotrexate Sodium USP/BP equivalent to 50mg of Methotrexate sterile freeze dried powder for reconstitution with water for injection BP/USP for intramuscular, intravenous, and intra-arterial use. Note: 1. This injection should be stable for minimum of 24 months when stored at a temperature range of 28'C - 32'C 2. Each vial should be labelled accordingly. Pack Size: 01 VIAL BOX			
53	01201001	Daunorubicin hydrochride inj.20mg vial Daunorubicin Hydrochloride for injection USP, 20mg Each vial to contain 20mg of Daunorubicin Hydrochloride USP with mannitol as sterile dry powder for reconstitution immediately before use for intramuscular and intravenous use. Note: 1. This injection should be stable for a minimum of 24 months when stored at a temperature range of 28'C - 32'C 2. Each vial should be labelled accordingly. Pack Size: 01 VIAL BOX	4,000	VIAL	4,000 Vials – 01 st Jul. 2022
54	01202204	Methotrexate injection 1g vial	4,000	VIAL	4,000 Vials –

					01 st Sep. 2022
		Methotrexate injection BP/USP 1g/10ml Each 10ml vial to contain Methotrexate Sodium BP/USP equivalent to 100mg/ml Methotrexate in water for injection BP/USP for intramuscular, intravenous use. OR Methotrexate for injection USP 1g Each vial to contain Methotrexate Sodium USP/BP equivalent to 1g of Methotrexate as sterile freeze dried powder for reconstitution with water for injection BP/USP for intramuscular, intravenous use. Note: 1. This injection should be stable for minimum of 24 months when stored at a temperature range of 28'C-32'C. 2. Each vial should be labelled accordingly. Pack Size: 01 VIAL BOX			
55	01203501	Hydroxyurea capsule 500mg	300,000	CAPS	300,000 Caps –
		Hydroxyurea/Hydroxycarbamide BP 500mg capsules. Each capsule to contain 500mg of Hydroxyurea/Hydroxycarbamide BP. OR Hydroxyurea capsule USP. Each capsule to contain 500mg of Hydroxyurea USP. Note: 01.The shelf life of the product should be minimum of 24 months Pack Size: 01 CAP X 100 BOX			01 st Oct. 2022
56	01201201	Epirubicin hydrochloride Inj.10mg vial	250	VIALS	250 Vials –

					01 st Oct. 2022
		Epirubicin Hydrochloride for injection 10mg vials. Each vial to contain 10mg of Epirubicin Hydrochloride (CAS-56390-09-01) as sterile dry powder for reconstitution with water for injection BP/USP before use for intravenous infusion OR Epirubicin Hydrochloride injection 10mg/5ml Each 5ml vial to contain 10mg of Epirubicin Hydrochloride (CAS-56390-09-1) in a suitable vehicle for intravenous infusion. Note: 1. This injection should be stable for a minimum of 24 months when stored within a temperature range of 2'C - 8'C 2. Each vial should be packed in light resistant box. 3. Each vial should be labelled accordingly Pack Size: 01 VIAL X BOX			
57	01206901	Letrozole tablet 2.5mg Letrozole Tablet 2.5mg Each coated tablet to contain Letrozole 2.5mg Note: 01.The shelf life of the product should be minimum of 24 months	40,000	TABS	40,000 Tabs – 01 st Oct. 2022
		Pack Size: 01 TAB X 100 BOX			